KENNA RASIKLAL

“The new fees going into effect in July 2022 will only increase fees by about 3% across the board.”

Kenna Rasiklal
Principal Consultant
Asia Actual Singapore

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

Sign Up For Our Newsletter to Stay Informed

Sign Up

The Health Science Authority to Raise Review Fees in Singapore in July 2022

Published on: January 20th, 2022

Singapore’s Health Science Authority (HSA) has announced that they will increase their review fees in Singapore for all registration routes in July 2022. The increased government fees are equivalent to about a 3% increase across the board. For a complete list, please visit the HSA’s official revised schedule of fees. Singapore remains a beacon of regulatory efficiency and market entrance for international medical device manufacturers selling in Asia. With a high standard of living and several leading hospitals in the region, Singapore is an important market for all manufacturer serious about establishing their brand in Asia.

Current fees can be found here and more information on the regulatory process can be found here.

New HSA Government Review Fees in Singapore

The HSA has announced that they will be increasing fees across the board in July 2022. While most fees have increased by about 3%, some of the updated fees can be found below.

Fees Class B Class B (New) Class C Class C (New) Class D Class D (New) Class D with a registrable drug Class D with a registrable drug (New)
Application fee $515 $530 $515 $530 $515 $530 $515 $530
Immediate route fee $925 $950 $3,090 $3,180 N.A. N.A. N.A. N.A.
Expedited route fee N.A. N.A. $3,090 $3,180 $5,560 $5,730 N.A. N.A.
Abridged route fee $1,850 $1,910 $3,605 $3,710 $5,870 $6,050 $10,200 $10,300
Full route fee $3,605 $3,710 $5,870 $6,050 $11,600 $11,800 $75,200 $75,400

All fees are in Singapore dollars. S$1,000 = US$705 as of January 2022

New Change Notification Review Fees in Singapore

The Health Science Authority has also updated the change notification review fees in Singapore by about 3%.

The updated change notification fees are as follows:

Notification Changes  Class B (Old) Class B (New) Class C (Old) Class C (New) Class D (Old) Class D (New)
Administrative $515 $530 $515 $530 $515 $530
Review $515 $530 N.A. N.A. N.A. N.A.
Technical N.A. N.A. $1,750 $1,800 $2,880 $2,970

All fees are in Singapore dollars. S$100 = US$70.5 as of January 2022

New Retention Fees in Singapore

Singapore’s Health Science Authority requires license holder pay an annual retention fees to maintain the SMDR listing and has also slightly increased these fees.

Classification 2021 Fees New Fees

(beginning July 1, 2022)
Class B $36 $37
Class C $62 $64
Class D $124 $128
Class D with registrable drug $124 $128

All fees are in Singapore dollars. S$100 = US$70.5 as of January 2022

Grow with Us

Asia Actual specializes in helping medical device manufacturers grow their sales in Asia with experienced, bi-lingual commercial and regulatory experts on the ground in Singapore. Contact Asia Actual today if you have questions or need support importing medical products into Singapore.

Blog Posts

Australia SaMD Transition Deadline

Australia’s SaMD Regulatory Deadline

Beginning on November 1st, 2024, Australia's Therapeutic Goods Administration will implement new rules surrounding software as a medical device (SaMD). While some SaMD will require additional regulatory requirements, other SaMD will be exempted from some, or excluded completely, from the new regulations.
Read more
Thai FDA Documentation Exemptions for Concise and Full Regulatory Pathways

Thai FDA Regulatory Documentation Exemptions

March 12, 2024: the Thai FDA released draft guidance updating the list of required documentation for Full and Concise Evaluation. For manufacturers registering a medical device in Thailand, certain documents are no longer required.
Read more
Hong Kong MDD adds Singapore HSA to Reference Country List

Hong Kong MDD Adds Singapore as Reference Country

Starting April 2nd, 2024, the Hong Kong Medical Device Division (MDD) accepts, on a regular basis, the marketing approvals obtained from the the Health Sciences Authority (HSA) of Singapore as a support of compliance of medical device to the "Essential Principles of Safety and Performance of Medical Devices" (Technical Reference: TR-004) under MDACS.
Read more